Repurposed Drugs is under clinical development by Luminous Mind and currently in Phase I for Depression. According to GlobalData, Phase I drugs for Depression have a 72% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Repurposed Drugs’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Repurposed Drugs overview
The repurposed drugs are under development for the treatment of anxiety, depression and other central nervous system disorders.
Luminous Mind overview
Luminous Mind is a biotechnology company specializes in the development of treatments for Central Nervous System (CNS) disorders. It is involved in the discovery and development of therapeutic solutions, which includes repurposing existing, abandoned, and developmental compounds for new indications. The company’s products provide treatments for a range of CNS disorders such as depression, PTSD, pain, anxiety, and addiction. It is headquartered in Cambridge, Massachusetts, the US.
For a complete picture of Repurposed Drugs’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
